288 related articles for article (PubMed ID: 31222484)
1. Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy.
Tarone L; Barutello G; Iussich S; Giacobino D; Quaglino E; Buracco P; Cavallo F; Riccardo F
Cancer Immunol Immunother; 2019 Nov; 68(11):1839-1853. PubMed ID: 31222484
[TBL] [Abstract][Full Text] [Related]
2. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
[TBL] [Abstract][Full Text] [Related]
3. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
Riccardo F; Tarone L; Camerino M; Giacobino D; Iussich S; Barutello G; Arigoni M; Conti L; Bolli E; Quaglino E; Merighi IF; Morello E; Dentini A; Ferrone S; Buracco P; Cavallo F
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580930
[TBL] [Abstract][Full Text] [Related]
4. Translational oncotargets for immunotherapy: From pet dogs to humans.
Mestrinho LA; Santos RR
Adv Drug Deliv Rev; 2021 May; 172():296-313. PubMed ID: 33705879
[TBL] [Abstract][Full Text] [Related]
5. Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.
Barutello G; Rolih V; Arigoni M; Tarone L; Conti L; Quaglino E; Buracco P; Cavallo F; Riccardo F
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29534457
[TBL] [Abstract][Full Text] [Related]
6. A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma.
Tarone L; Giacobino D; Camerino M; Maniscalco L; Iussich S; Parisi L; Giovannini G; Dentini A; Bolli E; Quaglino E; Merighi IF; Morello E; Buracco P; Riccardo F; Cavallo F
Mol Ther; 2023 Aug; 31(8):2342-2359. PubMed ID: 37312451
[TBL] [Abstract][Full Text] [Related]
7. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
Mason NJ
Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
[TBL] [Abstract][Full Text] [Related]
8. A Role for Dogs in Advancing Cancer Immunotherapy Research.
Dow S
Front Immunol; 2019; 10():2935. PubMed ID: 32010120
[TBL] [Abstract][Full Text] [Related]
9. Canine and murine models of osteosarcoma.
Beck J; Ren L; Huang S; Berger E; Bardales K; Mannheimer J; Mazcko C; LeBlanc A
Vet Pathol; 2022 May; 59(3):399-414. PubMed ID: 35341404
[TBL] [Abstract][Full Text] [Related]
10. Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.
Fenger JM; London CA; Kisseberth WC
ILAR J; 2014; 55(1):69-85. PubMed ID: 24936031
[TBL] [Abstract][Full Text] [Related]
11. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.
Igase M; Nemoto Y; Itamoto K; Tani K; Nakaichi M; Sakurai M; Sakai Y; Noguchi S; Kato M; Tsukui T; Mizuno T
Sci Rep; 2020 Oct; 10(1):18311. PubMed ID: 33110170
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy.
Bergman PJ
Vet Clin North Am Small Anim Pract; 2010 May; 40(3):507-18. PubMed ID: 20471533
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma.
Mason NJ; Gnanandarajah JS; Engiles JB; Gray F; Laughlin D; Gaurnier-Hausser A; Wallecha A; Huebner M; Paterson Y
Clin Cancer Res; 2016 Sep; 22(17):4380-90. PubMed ID: 26994144
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment.
MacEwen EG
Cancer Metastasis Rev; 1990 Sep; 9(2):125-36. PubMed ID: 2253312
[TBL] [Abstract][Full Text] [Related]
15. Naturally occurring tumors in dogs as comparative models for cancer therapy research.
Hahn KA; Bravo L; Adams WH; Frazier DL
In Vivo; 1994; 8(1):133-43. PubMed ID: 8054503
[TBL] [Abstract][Full Text] [Related]
16. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.
Piras LA; Riccardo F; Iussich S; Maniscalco L; Gattino F; Martano M; Morello E; Lorda Mayayo S; Rolih V; Garavaglia F; De Maria R; Lardone E; Collivignarelli F; Mignacca D; Giacobino D; Ferrone S; Cavallo F; Buracco P
Vet Comp Oncol; 2017 Sep; 15(3):996-1013. PubMed ID: 27146852
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
Razmara AM; Farley LE; Harris RM; Judge SJ; Lammers M; Iranpur KR; Johnson EG; Dunai C; Murphy WJ; Brown CT; Rebhun RB; Kent MS; Canter RJ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631708
[TBL] [Abstract][Full Text] [Related]
18. Canine Melanomas as Models for Human Melanomas: Clinical, Histological, and Genetic Comparison.
Prouteau A; André C
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31262050
[TBL] [Abstract][Full Text] [Related]
19. Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model.
Crossley RA; Matz A; Dew T; Kalinauskas A; Faucette N; Poff B; Silbart LK; Suckow MA
Anticancer Res; 2019 Apr; 39(4):1699-1703. PubMed ID: 30952708
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen.
Gyorffy S; Rodriguez-Lecompte JC; Woods JP; Foley R; Kruth S; Liaw PC; Gauldie J
J Vet Intern Med; 2005; 19(1):56-63. PubMed ID: 15715049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
